

IMMUNOPOTENTIATORS IN MODERN VACCINES

7-9 May 2014, Sao Rafael Atlantic Hotel, Albufeira, Algarve, Portugal

FINAL ORAL PROGRAMME

IMV 2014

SCIENTIFIC ADVISORY PANEL/MODERATORS

Conference Co-Chairmen: Virgil Schijns (*Wageningen University, Wageningen, The Netherlands*) and Jim Brewer (*University of Glasgow, UK*)

Derek O'Hagan (*Novartis Vaccines, USA*)

Gwyn Davies (*St. George's University of London, UK*)

Martin Bachmann (*University of Zurich, Zurich, Switzerland*)

Adriana Baz Morelli (*CSL Limited, Australia*)

Ali Harandi (*Gothenburg University, Sweden*)

Rob Lambkin-Williams (*Retroscreen Virology, London, UK*)

Nathalie Garcon (*GSK Biologicals, Rixensart, Belgium*)

Geert Vanden Bossche (*UNIVAC LLC, Belgium*)

Steve Reed (*IDRI, Seattle, Washington, USA*)

Heather Davis (*Pfizer Vaccines Research, Ottawa, Canada*)

Dennis Christensen (*Statens Serum Institut, Copenhagen, Denmark*)

Niranjan Sardesai (*INOVIO Inc., Blue Bell, Pennsylvania, USA*)

SANOFI PASTEUR 



European Adjuvant
Advisory Committee

 aldevron

DNAvaccine.com


BRENNTAG 

inovio
PHARMACEUTICALS

 NOVARTIS
VACCINES



DYNAVAX
DYNAX TECHNOLOGIES

NatureGeneTherapy 



 IDRI
Infectious Disease Research Institute

IMMUNE DESIGN 

 VISCOGEL

 Mucosis
Vaccines that mimic nature

EUROCINE  VACCINES

 ABIVAX

10.00-11.00

Registration & Coffee

**SESSION 1:
PLENARY SESSION**

Moderator: James Brewer (*University of Glasgow, Glasgow, UK*)

11.00-11.20

'Welcome and introduction to Immunopotentiators in Modern Vaccines'

Virgil Schijns (*Wageningen University, Wageningen, The Netherlands*)

11.20-11.50

'What is the next generation of adjuvant?'

Derek O'Hagan

(*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

11.50-12.20

'Adjuvants: Where they go, what they do and how they do it'

Jim Brewer (*University of Glasgow, Glasgow, UK*)

12.20-12.50

'Re-thinking vaccinology'

Geert Vanden Bossche (*Univac LLC, Belgium*)

12.50-14.00

Lunch Break

Seven Seas Restaurant

**SESSION 2:
MUCOSAL**

Moderator: Geert Vanden Bossche (*Univac LLC, Belgium*)

14.00-14.30

'Immunopotentiators for mucosal immunity'

Ali Harandi (*University of Gothenburg, Gothenburg, Sweden*)

14.30-14.50

'Intranasally administered Endocine™ formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets'

Koert J. Stittelaar, Anna-Karin Maltais, Edwin J.B. Veldhuis Kroeze,

Geert van Amerongen, Leon de Waal, Marcle L. Dijkshoorn,

Gabriel P. Krestin, Jorma Hinkula, Hans Arwidsson, Alf Lindberg

and Albert D.M.E. Osterhaus

(*Viroclinics Biosciences, Rotterdam, The Netherlands*)

14.50-15.10

'Triterpen saponins of plant origin as an efficient immunopotentiators for mucosal immunization'

V.E. Berezin, A.P. Bogoyavlenskiy, P.G. Alexyuk and I.A. Zaitceva

(*Institute of Microbiology and Virology, Almaty, Kazakhstan*)

15.10-15.40

'An intranasal proteosomes vaccine: An update'

Rob Lambkin-Williams (*Retroscreen Virology Ltd, London, UK*)

15.40-16.10

Tea Break

**SESSION 3:
ADJUVANTS I**

Moderator: Dennis Christensen

(*Statens Serum Institut, Copenhagen, Denmark*)

16.10-16.40

'Adjuvant comparison across models through system vaccinology'

Arnaud Didierlaurent (*GSK Vaccines, Rixensart, Belgium*)

16.40-16.55

'CAF01: A safe and effective liposome adjuvant that promotes strong and long-lived antigen specific T cell responses in humans'

Dennis Christensen (*Statens Serum Institut, Copenhagen, Denmark*)

16.55-17.20

'Evaluation of new adjuvant components *in vitro* may lead to false-negative conclusions: A study on synthetic MMG analogues'

Karen Smith Korsholm (*Statens Serum Institut, Copenhagen, Denmark*) &

Birte Martin-Bertelsen (*University of Copenhagen, Copenhagen, Denmark*)

17.20-17.40

'Influence of the molecular structure of mono and diester analogues of trehalose-6,6' -dibehenate (TBD) on biophysical characteristics and receptor interaction with Mincle'

Rie Selchau Kallerup, Birte Martin-Bertelsen, Henrik Franzyk,

Ana Yanhnmur, Dennis Christensen, Karen Smith Korsholm,

Alexandra Huber, Roland Lang and Camilla Foged

(*University of Copenhagen, Copenhagen, Denmark*)

17.40-18.30

IMV 2014 Welcome Reception

Will be held in the Chill-Out Bar

**SESSION 4:
PLENARY**

Moderator: Adriana Baz Morelli (*CSL Limited, Melbourne, Australia*)

09.00-09.30

'Steering immune responses by new versatile terpen particles'

Bror Morein (*MoreinX AB/Uppsala University, Uppsala, Sweden*)

09.30-10.00

'Cellular targeting of immunostimulators'

Dennis Christensen (*Statens Serum Institut, Copenhagen, Denmark*)

10.00-10.30

'Polyphosphazene immunopotentiators and their multimeric complexes with antigen activate human dendritic cells and facilitate antigen presentation to T-cells'

Alexander K. Andrianov, David J. Dowling, Alexander Marin and Ofer Levy (*Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA*)

10.30-11.00

Coffee Break

**SESSION 5:
DELIVERY**

Moderator: Derek O'Hagan

(*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

11.00-11.30

'Thermoreversible emulsion for the delivery of antigens and immunopotentiators'

Jean Haensler (*Sanofi-Pasteur, Marcy-l'Etoile, France*)

11.30-11.50

'Inter-bilayer cross-linked multi-lamellar vesicles (ICMVs) for efficient co-delivery of antigen and adjuvant payloads'

Adrienne Li, Darrell Irvine, Jackson Eby, Peter Demuth and Alan R. Shaw (*Vedantra Pharmaceuticals, Cambridge, Massachusetts, USA*)

11.50-12.20

'Potentiation of DNA vaccine responses with molecular adjuvants and immunomodulators'

Kate Broderick, Laurent Humeau, Amir Khan and Nirnajan Y. Sardesai (*Inovio Inc, Blue Bell, Pennsylvania, USA*)

12.20-12.40

'Structural characterization of novel mycobacterial lipid analogues: Promising immunopotentiators for subunit vaccines'

Birte Martin-Bertelsen, K.S. Korsholm, D. Christensen, H. Farnzyk, A. Yaghmur and C. Foged (*University of Copenhagen, Copenhagen, Denmark*)

12.40-13.00

'Poly(I:C) coated micro- and nanoparticles induce dendritic cell activation independent of particle shape'

Julia Engert, Roman Mathaes, Ahmed Besheer, Teruna J. Siahaan and Gerhard Winter (*Ludwig-Maximilians-University, Munich, Germany*)

13.00-14.00

Lunch Break

Seven Seas Restaurant

**SESSION 6:
ADJUVANTS II**

Moderator: Jean Haensler (*Sanofi-Pasteur, Marcy-l'Etoile, France*)

14.00-14.30

'The Novartis TLR agonist screening program'

Derek O'Hagan (*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

14.30-14.55

'Safety and efficacy of the ABX196 adjuvant on clinical trial'

Vincent Serra (*Abivax, Rheims, France*)

14.55-15.20

'On the formulation studies to abrogate ABX196 immunodulator delivery into the liver'

Vincent Serra (*Abivax, Rheims, France*)

15.20-15.40

'An *O.volvulus*-derived protein adjuvant for influenza vaccine sparing'

Sara Lustigman, Jiu Jiang, Erin M. Fisher, Nancy Tricoche, Donna M. Murasko and Hao Shen (*New York Blood Center, New York, USA*)

15.40

Tea Break and Leisure Afternoon

**SESSION 7:
PLENARY**

Moderator: Jim Brewer (*University of Glasgow, Glasgow, Scotland, UK*)

09.00-09.30

'Adaptive immunity enhancing innate immunity'

Martin Bachmann (*University of Oxford, Oxford, UK / University of Zurich Hospital, Zurich, Switzerland*)

09.30-10.00

'Induction of prophylactic or therapeutic protection against tumors using ISCOMATRIX adjuvant in mouse models of cancer'

Adriana Baz Morelli (*CSL Limited, Melbourne, Australia*)

10.00-10.30

'The maturing rationale for Matrix-M adjuvanted vaccines: Phase 2 and beyond'

Karin Lövgren Bengtsson (*Novavax AB, Uppsala, Sweden*)

10.30-10.50

Coffee Break

**SESSION 8:
VACCINES**

Moderator: Ali Harandi (*University of Gothenburg, Gothenburg, Sweden*)

10.50-11.20

'ADITEC – Ongoing high impact EU-funded vaccine/adjuvant research project update'

Donata Medagliani (*University of Siena, Siena, Italy*) and Ali Harandi (*University of Gothenburg, Gothenburg, Sweden*)

11.20-11.50

'EDCTP2: New opportunities for vaccine research in neglected and poverty-related diseases'

Ole Oleson (*EDCTP, The Hague, The Netherlands*)

11.50-12.15

'An intranasal chitosan vaccine: Update'

Rob Lambkin Williams (*Retroscreen Virology Ltd, London, UK*)

12.15-12.40

'Improved Pertussis combination vaccines using novel adjuvants'

V. Agnolon, C. Bruno, B. Galletti, E. Mori, R. Leuzzi, M. Soriani, L. Galli Stampino, U. D'Oro, M. Ugozzoli, M. Pizza, D. O'Hagan and B. Baudner (*Novartis Vaccines & Diagnostics Research Center, Siena, Italy*)

12.40-14.00

Lunch Break

Seven Seas Restaurant

**SESSION 9:
ADJUVANTS III**

Moderator: Martin Bachmann (*University of Oxford, Oxford, UK / University of Zurich Hospital, Zurich, Switzerland*)

14.00-14.25

'Immunopotentiators associated with chitosan particles as vaccine adjuvants'

Olga Borges, Dulce Bento and Filipa Lebre (*Universidade de Coimbra, Coimbra, Portugal*)

14.25-14.50

'Polymer-based platforms for vaccination'

Daniel Bonner, Laura Jeanbart, Alexandre De Titta, Sachiko Hirose, David Scott Wilson, Marie Ballester, Evan Scott, Melody Swartz, Jeffrey Hubbell (*EPFL, Lausanne, Switzerland*)

14.50-15.15

'New automated process optimized for emulsified vaccine preparation in the hospital'

Aude Puget (*SEPPIC, Paris, France*)

**SESSION 10:
CLOSING PLENARY LECTURE**

Moderator: Ali Harandi

(*University of Gothenburg, Gothenburg, Sweden*)

15.15-15.40

'The Innovative Medicines Initiative: Moving vaccine research forward through public-private partnership'

Elisabetta Vaudano (*Innovative Medicines Initiative, Brussels, Belgium*)
(Presented by Ole Olesen (*EDCTP, The Hague, The Netherlands*))

15.40

Closing Remarks

Virgil Schijns (*Wageningen University, Wageningen, The Netherlands*)

Departure

* This final programme is correct at the time of printing. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.